pliantrx.com - חוב לטווח קצר להון PLRX

Pliant Therapeutics (PLRX) develops innovative anti-fibrotic treatments, leveraging partnerships with industry giants and the joint development of molecules. Its diversification strategy covers lung and liver therapies, expanding its target markets. This chart of share prices on the GURU.Markets platform shows a value of 0.02. A stable capital reserve ensures the execution of final-stage inhibitor trials, shielding the company from external volatility.

For Pliant Therapeutics (PLRX), which delegates manufacturing and clinical trials to external partners, minimizing current liabilities is critical for maintaining operational flexibility. The ratio of short-term loans to equity, reflected in the change in short-term debt levels relative to equity, measures the company's dependence on rapid refinancing, where a decreasing ratio confirms financial stability and reduces default risk.